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Abstract: In this study, we aim to gain insight in the germline mutation spectrum of ATM, BARD1,
BRIP1, ERCC4, PALB2, RAD51C and RAD51D in breast and ovarian cancer families from Spain.
We have selected 180 index cases in whom a germline mutation in BRCA1 and BRCA2 was previously
ruled out. The importance of disease-causing variants in these genes lies in the fact that they may
have possible therapeutic implications according to clinical guidelines. All variants were assessed by
combined annotation dependent depletion (CADD) for scoring their deleteriousness. In addition, we
used the cancer genome interpreter to explore the implications of some variants in drug response.
Finally, we compiled and evaluated the family history to assess whether carrying a pathogenic
mutation was associated with age at diagnosis, tumour diversity of the pedigree and total number of
cancer cases in the family. Eight unequivocal pathogenic mutations were found and another fourteen
were prioritized as possible causal variants. Some of these molecular results could contribute to cancer
diagnosis, treatment selection and prevention. We found a statistically significant association between
tumour diversity in the family and carrying a variant with a high score predicting pathogenicity
(p = 0.0003).
Keywords: HBOC; genetic testing; variant prioritisation; therapeutic selection; family history;
clinical guidelines
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1. Introduction
Genetic testing is a key tool for cancer prevention through family history analysis and the
identification of inherited mutations. Thus, testing for individuals at risk of hereditary breast and
ovarian cancer (HBOC) is encouraged to implement control and prevention measures through genetic
counselling [1]. Uncovering the genetic causes of HBOC cases enables early detection and prevention.
Due to its inheritable nature, family members may benefit from genetic counselling [2,3].
Although hereditary cancer accounts for a small proportion of the total cases, in absolute numbers
they represent a significant number of mutation carriers who can benefit from clinical management in
order to reduce morbidity and mortality [4].
After screening for BRCA1/2 genes, the underlying genetic predisposition remains elusive in a
proportion of high risk cancer cases. Therefore, we undertook screening of other genes in a cohort
of patients with a presumed genetic predisposition for breast and ovarian cancer, in whom germline
mutations in BRCA1 and BRCA2 were previously ruled out.
DNA repair defects prompt genetic instability, a well-known carcinogenic trigger. Therefore,
functional defects in any DNA repair gene can contribute to the accumulation of errors and, ultimately,
to cellular transformation. In fact, most HBOC susceptibility genes encode proteins which are involved
in DNA repair. Mutations in these genes compromise the effectiveness of DNA repair, leading to
genomic instability. Reciprocally, the accumulation of these mutations would be promoted by genomic
instability, and this mutagenic environment would eventually enhance tumour progression. Proteins,
such as ATM, BARD1, and Fanconi Anemia (FA) BRIP1, ERCC4, PALB2, RAD51C and RAD51D
proteins, are involved in DNA repair pathways and have previously been linked to HBOC susceptibility
associated with low to moderate risks [5,6].
Exploiting DNA repair defects of the mutated cells has emerged as a targeted therapy strategy.
Germline mutations in HBOC susceptibility genes not only confer cancer risk to carriers, but may
also determine the response to certain treatment options, providing the opportunity to customise
chemotherapy [7,8].
In Spain, particularly in our region, the standard practice for patients at high risk for HBOC is to
screen germline mutations in BRCA1 and BRCA2 genes. Consequently, the purpose of this work is to
investigate whether by increasing the number of genes tested (some BRCA-FA pathway genes involved
in HBOC susceptibility and ATM and BARD1 genes), more families could benefit from prevention
measures according to SEOM Clinical Guidelines [3]. Furthermore, it aims to be a first approach to
select other clinically useful genes for better management in our BRCA negative families; and, hence,
to implement a personalised panel for families that meet high-risk criteria in our target population.
2. Results
2.1. Mutation Screening
All 180 individuals included in this study were previously screened for BRCA1/2 point mutations
and large rearrangements, with negative results. We previously published a PALB2 deleterious
mutation that was identified in this cohort [9].
To further characterise this 180 index-case cohort, we selected some BRCA-FA pathway genes first.
Therefore, seven additional genes implicated in HBOC predisposition and DNA damage response
were analysed: ATM, BARD1, BRIP1, ERCC4, PALB2, RAD51C and RAD51D. All the variants identified
in the cohort are listed in Table S1.
We found eight pathogenic variants in 180 unrelated probands (4.4%): c.3663G>A (p.Trp1221*),
c.4776+2T>C and c.8934_8935delTG (p.Glu2979Alafs*9) in ATM; c.484C>T (p.Arg162*) in BRIP1;
c.1251T>A (p.Cys417*) and c.584+1G>A in ERCC4; c.1857delT (p.Phe619Leufs*9) in PALB2 and
c.94_95delGT (p.Val32Phefs*38) in RAD51D. All mutations have already been reported in disease
databases (ClinVar, dbSNP, LOVD) or in literature [9,10]. The personal and family history for each
pathogenic variant is described in Table 1.
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Table 1. Pathogenic variants identified in the 180 index patients.
Gene c.DNA Change Protein Change ACMG Rules Proband Cancer Type (Age)
Family History Cancer Type (Age)
First-Degree-Relatives Second-Degree-Relatives Third-Degree-Relatives
ATM c.3663G>A p.Trp1221 * PVS1, PM2 Br (43) Col (50) Br (36), Br (25), Ov (62) Br (57), Ov (53)
ATM c.4776+2T>C - PVS1, PM2 Br (52)Ov (60)
Pan (29), Pan (58),
Br (47), Col (67),
Col + Br (66,74)
CUP (78)
Gas (58), Gas (65),
Gas (70), Gas (72),
Br + Col (66,74)
ATM c.8934_8935delTG p.Glu2979Alafs*9 PVS1, PM2 Br (47) Ov (35) Gas (23), Br (60) Ov (23), Ov (33),Thy (34), Thy (41)
BRIP1 c.484C>T p.Arg162 * PVS1, PM1, PM2 Ov (79)Mel (81)
Gas (50), Br (32),
H&N (54), CUP (82),
CUP (56)
ERCC4 c.1251T>A p.Cys417 * PVS1, PM1, PM2 BilBr (59-59) End (47), End (51),End + Col (57,59), Gas (80) Br (70), Gas (75) Br (72)
ERCC4 c.584+1G>A - PVS1, PM2 Br (53) Br (55) Col (45), Br (54), Br (33),Br (57), Pr (84)
Col (36), Ute (47),
Br (53), Br (55)
PALB2 c.1857delT p.Phe619Leufs*9 PVS1, PM1, PM2 Ov (33) Br (36), Liv (78) End (55), Lun (62) Leu (n.a)
RAD51D c.94_95delGT p.Val32Phefs*38 PVS1, PM1, PM2 Ov (44) Cvx (36), Gas (79) BilBr (84) Col (80)
Cancer types are abbreviated as following: Br, breast; BilBr, bilateral breast; Ov, ovarian; Gas, gastric; Col, colon; Pan, Pancreas; Thy, thyroid; H&N, head and neck; Pr, prostrate; Cvx, cervix;
Ute, uterus; Kid, kidney; CUP, cancer of unknown primary origin. The age of diagnosis is indicated in parentheses, n.a not available data. * nonsense mutations; the nucleotide substitution
introduce premature termination codon.
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Cancer types are abbreviated as following: Br, breast; BilBr, bilateral breast; Ov, ovarian; Gas,
gastric; Col, colon; Pan, pancreas; Thy, thyroid; H&N, head and neck; Pr, prostrate; Cvx, cervix; Ute,
uterus; Kid, kidney; CUP, cancer of unknown primary origin. The age of diagnosis is indicated in
parentheses, n.a not available data.
2.2. Segregation Analysis
Segregation analysis was performed for some BRIP1, RAD51D and ATM pathogenic mutations.
Pedigrees showing the analysis results are displayed in Figure 1. Segregation with the cancer phenotype
in certain variants was incomplete in some families: such as the family with c.94_95delGT RAD51D
mutation (Figure 1b) and the family with c.3663G>A ATM variant (Figure 1c). For the family with
c.8934_8935delTG variant in ATM (Figure 1d) a first degree cancer affected relative (Figure 1d, III.12)
turned out to be negative.
Cancers 2020, 12, 2151 5 of 17 
 
2.2. Segregation Analysis 
Segregation analysis was performed for some BRIP1, RAD51D and ATM pathogenic mutations. 
Pedigrees showing the analysis results are displayed in Figure 1. Segregation with the cancer 
phenotype in certain variants was incomplete in some families: such as the family with c.94_95delGT 
RAD51D mutation (Figure 1b) and the family with c.3663G>A ATM variant (Figure 1c). For the family 
with c.8934_8935delTG variant in ATM (Figure 1d) a first degree cancer affected relative (Figure 1d, 
III.12) turned out to be negative. 
 
Figure 1. Segregation of BRIP1, RAD51D and ATM pathogenic mutations. (a) Family with c.484C>T 
(p.Arg162*) BRIP1 mutation, (b) Family with c.94_95delGT (p.Val32Phefs*38) RAD51D mutation, (c) 
Family with c.3663G>A (p.Trp1221*) ATM variant; (d) Family with c.8934_8935delTG 
(p.Glu2979Alafs*9) variant in ATM. Index cases are indicated by an arrow. Confirmed mutation 
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is specified when known. Ov (ovarian), Mel (melanoma), Gas (gastric), Thy (thyroid), Liv (liver), Lung 
(lung), Br (breast), H&N (head and neck), Col (colon), Cvx (cervix) and CUP (unknown primary 
tumour). 
Several additional variants possibly impacting the function of the protein were identified in our 
cohort. These can be found above the corresponding protein schemes (Figure 2). 
Figure 1. Segregation of BRIP1, RAD51D and ATM pathogenic mutations. (a) Family with
c.484C>T (p.Arg162*) BRIP1 mutation, (b) Family with c.94_95delGT (p.Val32Phefs*38) RAD51D
mutation, (c) Family with c.3663G>A (p.Trp1221*) ATM variant; (d) Family with c.8934_8935delTG
(p.Glu2979Alafs*9) variant in ATM. Index cases are indicated by an arrow. Confirmed mutation carriers
are indicated by a “+” sign and non-carriers by a “−” sign. Age at diagnosis and cancer type is specified
when known. Ov (ovarian), Mel (melanoma), Gas (gastric), Thy (thyroid), Liv (liver), Lung (lung),
Br (breast), H&N (head and neck), Col (colon), Cvx (cervix) and CUP (unknown primary tumour).
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Several additional variants possibly impacting the function of the protein were identified in our
cohort. These can be found above the corresponding protein schemes (Figure 2).
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Figure 2. Potentially damaging missense variants. Pathogenic and missense variants with possible
functional impact are presented above the correspondin protein scheme (MutationMapper tool
from cBioPortal for Cancer Genomics). Most of the variants were listed in he ExAC database
(Exome Aggregatio Consortium, non-Finnish European ) ith minor allele frequency (MAF) < 0.01.
2.3. Variant Prioritisation
In order to prioritise the filtered variants, both in silico functional assessment using the CADD
algorithm (Figure 3) and a review of the possible implications of any mutations in drug response were
conducted. The higher the CADD score, the greater the likelihood that this variant will be deleterious.
A CADD score >25 was previously suggested as cut-off for of a damaging effect. Indeed, all pathogenic
mutations surpassed that CADD score (33.6 ± 5.8). After the analysis, a total of 22 variants presented
with a CADD score >25 (“high-CADD score” onwards) (Figure 3).
Interestingly, for two putative splicing variants, CADD analysis returned a high score: one
of them, c.584+1G>A in ERCC4 was previously tested by our group at cDNA level resulting in a
exon 3 skipping: p.Ile131Serfs*2 [11]. The other one, c.4776+2T>C in ATM, has been previously
analysed in fibroblasts derived from a homozygous carrier [12]. In this work, we investigated the
effect of c.4776+2T>C splicing variant in cDNA. Thus, we performed a reverse transcription of the
patient RNA. An amplicon spanning exons 29 to 33 was amplified. The mutation carrier transcript
revealed two bands: a 769 base-pair (bp) band corresponding to the expected wild-type fragment
and an aberrant transcript band (604 bp), while controls only showed the wild-type band (Figure 4A).
The subsequent sequence of the 604 bp transcript revealed exon 31 skipping (r.4612_4776del165;
p.Val1538_Glu1592del55) (Figure 4).
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Figure 3. Circular barplot showing the distribution of CADD scores for different variants per gene.
Variants with CADD score > 25 are indicated by “*”. Apart from the loss of function protein variants,
other rare missense mutations were prioritised according to CADD-score. For ATM, p.Pro1054Arg,
p.Phe1463Cys, p.Arg1466Gly and p.Arg2654Cys; for BRIP1, p.Asp184Tyr and p.Gln740His; for ERCC4
p.Pro379Ser, p.Arg624Gln, p.Ile706Thr and p.Glu875Gly; for PALB2 p.Val932Met and p.Lys939Trp; for
RAD51C p.Thr287Ala; for RAD51D p.Ala210Val. Different drugs for which a response is predicted for
some variants with a CADD score >25 in several genes are indicated in the inner part of the circular
barplot. “ib” inhibitors.
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Figure 4. Characterization of the c.4776+2T>C variant of ATM. (a) PCR products were separated by a
2% agarose gel electrophoresis. The c.4776+2T>C variant caused the skipping of exon 31, resulting in a
product which is 165 nucl otides shorter than the full-length product (769 nucleotides). (b) Schematic
representation of the exo skipping caused by c.4776+2T>C ATM variant.
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2.4. Therapeutic Implications
In order to contribute to the clinical utility, we took into consideration the high-CADD score
variants considered by the cancer genome interpreter as genomic biomarkers of drug response with
different levels of clinical relevance. Hypothetically, alterations in some actionable cancer genes could
determine the treatment effect. Indeed, the precision oncology concept is based on selecting the
chemotherapy regimen according to the supposed implications of the mutational profile. The different
drugs for each gene are detailed in Figure 3.
For some of the mutations, drug responses are predicted. This information could be taken into
consideration to select some of the available inhibitors for cancer treatment. In that sense, as a potential
but inconclusive valuable information, seven patients harbouring suggested pathogenic variants could
benefit from targeted therapy options with ATR inhibitors, PARP1 inhibitors and DNA-PKc inhibitors.
In line with this targeted therapy based on synthetic lethality concept, some of the PALB2 variants
(p.Phe619Leufs*9, p.Val932Met and p.Leu939Trp) and the p.Thr287Ala variant in RAD51C could be
determining a response to PARP inhibitors. For the therapy with the traditional drugs (cisplatin and
other platinum compounds), we could expect a response in the ERCC4 and PALB2 mutation carriers.
2.5. Genotype-Phenotypic Correlations
We evaluated if high-CADD score variants (Figure 3) were associated with younger age at
diagnosis and a more diverse tumour spectrum.
We first compared the mean age at diagnosis between high-CADD score mutation carriers and
non-carriers (one-sided t-test p-value = 0.1673). These analyses showed, at a 5% level of statistical
significance, that carrying a variant with a high-CADD score was not associated with an earlier tumour
onset (mean age of diagnosis is the same in both groups).
Secondly, we checked whether carriers of a high-CADD score mutation showed greater
tumour-type diversity in the family (Figure 5). Pearson’s chi-squared test, with Yates’ continuity
correction, suggested an association between tumour diversity in the family, and the carrying of
a variant with a high CADD score (5% level of statistical significance (p = 0.0003)). In addition,
high-CADD score mutation carriers presented a higher number of cancer cases in the pedigree than
negative cases (6.4 vs 4.4 mean number of cases respectively); therefore, the condition of carrying
a high-CADD score mutation is associated with an increased burden of cancer cases in the family
(p-value = 0.0023).
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Figure 5. Personal and family cancer history of the different studied index cases. Index cases are
clustered according to their personal cancer history, such as "breast" or "ovarian" when they developed
ovarian or breast cancer, respectively. Each row represents the family pedigree of the index cases and
the columns represent the different types of tumours in the family where each colour indicates the
number of cases for a specific type of cancer. Col, colon; Gas, gastric; Pr, prostatic; CUP, cancer of
unknown primary origin; Lun, lung; H&N, head and neck; Pan, pancreatic; End, endometrial; Leu,
leukaemia; Kid, kidney; Liv, liver; Brain, brain; Ute, uterus; Thy, thyroid; Cvx, cervix; Bla, bladder;
Lym, lymphoma; Tes, testicular; Mel, melanoma; and Bon, bone cancer.
3. Discussion
The clinical management of HBOC families makes cancer prevention possible through the
identification of individuals at high-risk. High penetrance genes explain a small number of cases, while
it is also necessary to look for mutations in other moderate and low penetrance genes. Of these, genes
which are crucial in DNA repair and DNA damage response have been postulated as good candidates.
The main goal of this work was to detect mutations in other genes to explain inherited breast/ovarian
cancer predisposition, enabling the clinical management of the carrier families. Firstly, we focused on
some FA/BRCA pathway genes such as BRIP1, ERCC4, PALB2, RAD51C and RAD51D. Since ATM has
a pivotal role in the detection and response to DNA damage, and BARD1 binds BRCA1 mediating the
initial nucleolytic resection of DNA lesions and the recruitment of RAD51, we decided to examine
these key DNA damage response genes as well. The FA genes were screened by heteroduplex analysis
by capillary array electrophoresis (HA-CAE) [13] or high resolution melting analysis (HRMA) as these
techniques were used in our routine until 2018. Thereafter, we adopted NGS thus we decided to test
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ATM and BARD1 with this technology. Our results demonstrate that increasing the number of assessed
candidate genes, molecular diagnosis improves.
ATM had been known to be linked to breast cancer predisposition in BRCA-negative families [14,15].
Furthermore, ATM mutations have been found in ovarian cancer [16]. In accordance with this, we
identified three ATM pathogenic variants in the index-case with breast cancer, one of whom also
developed an ovarian cancer (Table 1). The patient II.5 (Figure 1C), diagnosed with breast cancer at the
age of 43, carried the ATM variant c.3663G > A. Her family had, on the paternal side, two very early
cancer cases at 25 (I.10) and 36 (I.11) years-old (Figure 1C). Unfortunately, DNA was not available for
segregation analysis.
The ATM c.8934_8935delTG variant was found in the III.12 breast cancer patient (Figure 1d).
Her daughter, IV.2, who carries the mutation, may benefit from prevention measures [2,3]. This mutation
was previously reported in an Ataxia-Telangiectasia family [17]. In addition, other cancer types in
this family have been associated with ATM mutations such as thyroid [18], ovarian [16] and breast
tumours [15].
The variant c.4776+2T>C in ATM (Figure 4), previously reported in a breast cancer case [19],
modifies a canonical splicing site, potentially resulting in a splicing disruption. In addition, cells from
an individual, homozygous for this mutation, showed an increased radio-sensitivity [12]. This mutation
was identified in a triple-negative breast cancer patient at 52 years-old and ovarian cancer at the age of
60. It is worth noting that several cancer types associated with pathogenic ATM mutations were all
present in her family (Table 1): three gastric cancer cases [20], two breast cancers [19], two pancreatic
cancers [21] and three colon cancers [22]. To assess the pathogenic effect of this mutation, we have
experimentally demonstrated that this genetic change causes an alteration of splicing (Figure 4).
Although this variant causes an in-frame deletion of 55 amino acid, it has been classified as pathogenic
(ClinVar, and ACGM guidelines).
The implication of pathogenic BRIP1 variants in ovarian cancer predisposition have been described
before [16,23]. The c.484C > T BRIP1 mutation was identified in an ovarian and melanoma cancer
patient (Figure 1a, II.12). Interestingly, the mutation was inherited by her daughter, who developed
breast cancer at age 32 (III.2).
Two ERCC4 loss of function variants have been identified in two breast cancer cases.
The c.584+1G>A mutation has been previously published as part of a Spanish collaborative study [11].
The patient has a strong breast cancer family history, with five affected women (Table 1). Unfortunately,
DNA of the other breast cancer cases was not available to confirm familial segregation. In fact,
three out of the five affected women died immediately after being diagnosed, so we assume tumour
aggressiveness. The other ERCC4 mutation—c.1251T>A—was identified in a bilateral breast cancer
case (Table 1). Three endometrial cancer cases (the mother and two sisters of the patient) and two
gastric tumours are the family antecedents. Other authors have associated ERCC4 mutations with
endometrial cancer [24,25] and colorectal [26]; however, until now, the relatives with endometrial
cancer have refused genetic testing. Both mutations are classified as pathogenic according to the
ACMG standards.
Only one pathogenic variant in the RAD51D gene- c.94_95delGT- was detected in an ovarian
cancer patient (Figure 1B individual III.1, Table 1). The association between RAD51D pathogenic
mutations and ovarian cancer has already been established [23,27–29], endorsing the causal role of the
c.94_95delGT RAD51D mutation in the patient’s pathogenesis. Furthermore, her son, III.3, carried
the mutation; accordingly, the following information could be taken into account for prevention and
follow-up: COSMIC database records RAD51D somatic mutations in gastric, prostatic, pancreatic and
liver tumours. In fact, germline RAD51D variants and susceptibility to prostate cancer has also been
described [30]. Clinical guidelines have been developed for some genes such as ATM, BRIP1, PALB2
and RAD51D [2,3,31], enabling genetic counselling.
A large proportion of the variants identified in genetic analysis present conflicts of
interpretation [32]; ambiguity concerning their molecular effect impairs clinical management. Therefore,
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it is essential to make an effort to classify these variants [33]. Hence, another goal of this work was to
characterise the spectrum of rare variants, other than pathogenic ones, which may lead to an increased
risk for breast/ovarian cancer predisposition. The CADD tool seems very useful for identifying causal
mutations with a high score of pathogenicity [34,35]. Moreover, it offers a practical and unbiased
approach for estimating the pathogenicity of human genetic variants by integrating many diverse
annotations into a single, quantitative score [35].
After CADD analysis, a total of 14 missense variants with high-CADD score were selected,
apart from the eight properly pathogenic mutations. Interestingly, two variants altering the splicing,
c.584+1G>A in ERCC4 and c.4776+2T>C in ATM, presented a high-CADD score, denoting a possible
link between CADD output and cDNA analysis.
In practice, the CADD score alone could not be used for variant classification, but the algorithm
might be useful for prioritising variants for further functional and segregation studies [35].
Current records of the response to certain drugs, depending on the genetic profile, can serve as a
reference [36] for the chemotherapy regimen choice. The main challenge in the genetic diagnosis of
hereditary cancer is to transfer the findings to clinical practice; integrating information from in silico
tools and drug response records to allow us to make these mutations useful.
In a pharmacological context, the Cancer Genome Interpreter compiles information about the
implications of these possible causal variants for drug response. It is worth noting that most of the
variants with a high-CADD score have been catalogued as driver mutations at the somatic level,
assuming that they confer an advantage to the cell, triggering the transformation. Regarding the
therapeutic approach, these relevant mutations may be used for drug selection: for PALB2 mutations,
a response of the tumours has been registered for PARP inhibitors [37,38], mitomycin C [39] and
platinum compounds [40]. for deleterious ERCC4 variants, the effectiveness of cisplatin is expected for
disrupting mutations [41]; PARP inhibitors are selectively toxic to tumours with RAD51C mutations [42],
and tumours with ATM mutations had a positive response to cisplatin [43], and inhibitors of PARP1 [37],
ATR [44,45] and DNA-PKc [46].
Tumour onset in hereditary cancer is expected to be a distinguishing feature from sporadic cases:
germline mutation would imply a high risk for early-onset cancer. According to this hypothesis, we
checked whether the mean age of diagnosis was different between high-CADD score mutation carriers
and non-carriers. Statistically, we could not discard the fact that the diagnosis age was the same in the
two compared groups. This could be due to sporadic tumours that appear earlier as a consequence
of other risk factors such as lifestyle. As a consequence, the inclusion of sporadic cancer cases in our
cohort is possible. The immediate impact of the inclusion of sporadic cases is the presence of samples
without genetic variants, which, at the same time, decrease the mean age of this group [47,48].
Conversely, a trend was observed upon close examination of the family information: carrying a
pathogenic or rare variants with high-CADD score mutation seems to be determined by the presence
of a family history with more cases and more diverse tumour types. Interestingly, the statistical
analysis confirmed this association between high-CADD score mutation carriers and family cancer
history: patients with these mutations presented more cancer cases and more tumour types in their
pedigrees. This supports the hypothesis that familial history is relevant in sample selection for cancer
predisposition [49]. In brief, we may face a possibly non-typified hereditary cancer syndrome, in view
of the family history profile of our positive families (tumour type diversity beyond breast and ovarian
cancer). In fact, different cancer syndromes have overlapping clinical features, so expanding the
analysed gene set might imply a higher diagnostic yield.
4. Materials and Methods
4.1. Patients
The selected 180 cases were screened for deleterious mutations in the BRCA1 and BRCA2 genes,
and resulting negatives. We have studied 180 probands from breast and ovarian cancer families
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meeting high-risk criteria, enrolled from the Regional Hereditary Cancer Prevention Program of
Castilla-León (Spain). The participants in this study are ovarian or breast cancer patients who have
first-degree ovarian cancer relatives in the same side of the family. Ethical approval for this study was
obtained from Comité Ético de Investigación Clínica (CEIC). Informed consent, family history and
clinical features were collected (The approval code from the ethical committee is PI-13-66 and it was
obtained at the meeting of the Clinical Committee on 03/21/2013).
4.2. DNA and RNA Extraction
Genomic DNA from peripheral blood was automatically extracted by Roche MagNaPure®
Compact, using the “MagNA Pure Compact Nucleic Acid Isolation Kit I—Large Volume”
(Roche Diagnostics, Penzberg, Germany), following the manufacturer’s instructions. RNA was
extracted from peripheral blood lymphocytes using the GeneMATRIX Human Blood RNA Purification
Kit (EURx, Gdánsk, Poland). DNA concentration was measured in a NanoDrop™ (NanoDrop 2000c,
ThermoFisher Scientific, Waltham, MA, USA).
4.3. Mutation Screening
The entire coding sequence and splicing sites of PALB2 and ERCC4 were screened using
HA-CAE [13]. RAD51C, RAD51D and BRIP1 were screened by HRMA.
RAD51C, RAD51D and BRIP1 specific primers were designed with the UMelt software [50] Ideally,
amplicons ranged from 100–250 bp with a single melting peak. Our design targeted the coding exons
and the corresponding exon/intron boundaries. Sequences of primers are available upon request.
PCR (HRMA were conducted in a LightCycler 480 Instrument (Roche Diagnostics, Penzberg,
Germany). All reactions were performed in 10 µL final volume. PCR annealing temperatures (Ta) and
MgCl2 concentrations were optimised for each amplicon, lastly confirmed by direct sequencing. In
brief, for PCR reactions, we used the LightCycler® 480 High-Resolution Melting Master Mix kit (Ref:
04909631001, Roche): Mix HRM Roche 1×, 2.5 mM MgCl2, (3.5 mM of MgCl2 when the amplification
was suboptimal), 2.5 µM each forward and reverse primers and 2 ng/µL of genomic DNA. Thermal
cycling consisted of an initial 10-minute hold at 95 ◦C, followed by 10 s hold at 95 ◦C, 15 s hold at the
specific Ta, and 20 s hold at 72 ◦C for 40 cycles. Consecutively, HRMA consisted in a 65 ◦C to 95 ◦C
melting gradient with a 0.02 ◦C/s ramp rate and continuous 25 acquisitions/◦C mode. The LightCycler
480 Software version 1.5 (Roche Diagnostics, Indianapolis, IN, USA) was used for the melting curve
analysis. After checking the melting curves, we selected the temperature to normalise data. When the
curves differed in shape and/or melting temperature, the corresponding samples were subsequently
sequenced. Primers were designed using Primer3 tool software (http://bioinfo.ut.ee/primer3-0.4.0/).
ATM and BARD1 were sequenced using MiSeq Technology at the Centre for Medical Genetics
Ghent, as previously described [51].
Mutation nomenclature was based on the following reference sequences: ATM NM_000051.3;
BARD1 NM_000465.3; BRIP1 NM_032043.2; ERCC4 NM_005236.2; PALB2 NM_024675.3; RAD51C
NM_058216.1; RAD51D NM_002878.3.
4.4. Sanger Sequencing
Direct automated Sanger sequencing was used to confirm the results detected by screening methods
and massive parallel sequencing. For that purpose, we used the BigDye Terminator Sequencing Kit
v3.1 (Applied Biosystems, Foster City, CA, USA) on an ABI 3100 DNA Sequencer (four capillaries;
Applied Biosystems). Co-segregation studies were conducted when possible.
4.5. RT-PCR
Variants predicted as disrupters of splicing in the Human Splicing Finder TM 3.0 (HSF) software
(http://www.umd.be/HSF3/) were selected to perform cDNA-based analysis. Total RNA isolated
from lymphocytes was reverse transcribed into cDNA using the Transcriptor First Strand cDNA
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Synthesis Kit (Roche), according to the manufacturer’s protocol. Subsequently, we performed a
PCR to evaluate the transcription. The products were separated in low melting 2% agarose gel and
visualised with RedSafe™ nucleic acid staining solution (iNtRON Biotechnology, Korea) Isolated bands
were extracted using NucleoSpin® Gel and PCR Clean-up (Macherey-Nagel, Düren, Germany) and
subsequently sequenced.
We designed the primer pair −29 Forward (5′-TGTGAGCAAGCAGCTGAAACAA-3′) and
33 Reverse (5′- TTCACCAGTGTGGTTTATTGCCA-3′)— to evaluate the transcript spanning exons
29–33 so as to characterise the splicing effect of the c.4776+2T>C ATM variant. The RT-PCR reaction
consisted of a 1X Buffer A, 0.5 µM forward and reverse primers, 0.32 mM dNTP Mix, 1 Unit of Kappa
Taq DNA Polymerase, 12 µL of the cDNA generated in a final volume of 100 µL. The cycling conditions
were denaturation at 95 ◦C for 3 min, 35 cycles at 95 ◦C for 30 s, 62 ◦C for 30 s, and 72 ◦C for 50 s,
followed by a final extension at 72 ◦C for 10 min.
4.6. In-Silico Analyses
Mutations with protein annotations were analysed using the MutationMapper (http://www.cbioportal.
org/mutation_mapper), the cancer genome interpreter (https://www.cancergenomeinterpreter.org) and
HSF. Mutations that lead to premature truncation of the protein, frameshift, nonsense, and splice
site, were classified as deleterious mutation. On the other hand, missense variants with minor
allele frequency (MAF) <0.01 according to ExAC data were selected to further in silico research
(hereinafter rare variants). Combined Annotation-dependent Depletion (CADD) was applied for
both deleterious mutations and rare variants. In the CADD method, the scaled- C-scores are related
with the top-ranked pathogenicity: to CADD-Score-10 you are in the top 10% of the disrupting
mutations, to CADD-Score-20, top 1%, CADD-Score-25, top 0.5% and to CADD-Score-30, 0.1%. CADD
integrates diverse annotations into a single score by contrasting variants that survived natural selection
with simulated mutations [35,52,53]. We considered variants with a CADD-score of >25 as possibly
pathogenic (top 0.5% of disrupting variants).
All data representations, including the circular Barplot (Figure 3) and Heatmap (Figure 5), were
made using the Complex Heatmap (https://doi.org/10.1093/bioinformatics/btw313) and ggplot2 [54]
packages with the R Project for Statistical Computing, v.3.5.1. (https://www.r-project.org.)
4.7. Variant Classification
Variants were classified as deleterious if they originated a premature stop codon, if they were
located in canonical splice sites, or if there was literature evidence (ACGM guidelines, ENIGMA
classification rules). The potential deleteriousness of the remaining rare variants was evaluated using
the CADD method.
4.8. Genotype-Phenotypic Correlations and Statistical Analysis
Personal and family data and mutation profiling of the samples were compiled and explored,
looking for genotype–phenotypic correlations. Statistical tests were carried out using the R Project
for Statistical Computing (v.3.5.1). A one-sided t-test was used for two-group means comparison,
and Pearson’s chi-squared test with Yates’ continuity correction was used to evaluate the association
between two categorical variables.
5. Conclusions
A large proportion of breast and ovarian cancer predisposition remains unexplained: analysis of
genes other than BRCA1 and BRCA2 is needed. We have contributed to the molecular diagnostics of
some HBOC families in whom previously BRCA1/2 was ruled out, analysing other low to moderately
penetrant genes. The detection of deleterious mutations and other prioritised variants in some of these
genes has a significant impact on clinical management. Nevertheless, further studies are needed to
enable prevention, early detection and treatment selection in HBOC. Our data suggest that carriers
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of variants affecting the function of the gene belong to families with more cancer cases and a greater
diversity of tumour types.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/8/2151/s1,
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